175 related articles for article (PubMed ID: 30105656)
1. Anti-Anginal Effectiveness and Tolerability of Trimetazidine Modified Release 80 Mg Once Daily in Stable Angina Patients in Real-World Practice.
Glezer MG; Vygodin VA;
Adv Ther; 2018 Sep; 35(9):1368-1377. PubMed ID: 30105656
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Long-acting Trimetazidine in Different Clinical Situations in Patients with Stable Angina Pectoris: Findings from ODA Trial.
Glezer MG; Vygodin VA;
Cardiol Ther; 2019 Jun; 8(1):69-78. PubMed ID: 30778909
[TBL] [Abstract][Full Text] [Related]
3. The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Durations: Results from the CHOICE-2 Study.
Glezer M;
Adv Ther; 2018 Jul; 35(7):1103-1113. PubMed ID: 29766461
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Trimetazidine in Patients with Stable Angina Pectoris of Various Durations: Results from ODA.
Glezer MG; Vygodin VA;
Cardiol Ther; 2020 Dec; 9(2):395-408. PubMed ID: 32430799
[TBL] [Abstract][Full Text] [Related]
5. Real-world Evidence for the Antianginal Efficacy of Trimetazidine from the Russian Observational CHOICE-2 Study.
Glezer M;
Adv Ther; 2017 Apr; 34(4):915-924. PubMed ID: 28220388
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Tolerability of Trimetazidine 80 Mg Once Daily in Patients with Stable Angina Uncontrolled with Bisoprolol-Based Therapy: The Modus Vivendi Observational Study.
Lopatin Y; Petrova P;
Cardiol Ther; 2022 Mar; 11(1):93-111. PubMed ID: 34958427
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of the antianginal effectiveness of trimetazidine in a new dosage form for a single dose, depending on the region of the Russian Federation. ODA trial results].
Glezer MG; Vygodin VA
Kardiologiia; 2019 Sep; 59(10S):52-63. PubMed ID: 31876462
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study.
Vitale C; Spoletini I; Malorni W; Perrone-Filardi P; Volterrani M; Rosano GM
Int J Cardiol; 2013 Sep; 168(2):1078-81. PubMed ID: 23200272
[TBL] [Abstract][Full Text] [Related]
9. Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study.
Chazov EI; Lepakchin VK; Zharova EA; Fitilev SB; Levin AM; Rumiantzeva EG; Fitileva TB
Am J Ther; 2005; 12(1):35-42. PubMed ID: 15662290
[TBL] [Abstract][Full Text] [Related]
10. [Adherence of patients with stable angina to treatment with trimetazidine MR and frequency of emergency medical care: results of the EFFECT study].
Glezer MG; Saĭgitov RT
Kardiologiia; 2012; 52(11):4-11. PubMed ID: 23237390
[TBL] [Abstract][Full Text] [Related]
11. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study.
Sellier P; Broustet JP
Am J Cardiovasc Drugs; 2003; 3(5):361-9. PubMed ID: 14728070
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes.
Meiszterics Z; Kónyi A; Hild G; Sárszegi Z; Gaszner B
J Comp Eff Res; 2017 Nov; 6(8):649-657. PubMed ID: 29148291
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of trimetazidine prolong in stable coronary artery disease. Multicenter, prospective, observational study, ONECAPS study].
Tomcsányi J; Szakács L
Orv Hetil; 2018 Sep; 159(38):1549-1555. PubMed ID: 30227735
[TBL] [Abstract][Full Text] [Related]
14. Clinical Acceptability Of Trimetazidine Modified-Release 80 mg Once Daily Versus Trimetazidine Modified-Release 35 mg Twice Daily In Stable Angina Pectoris.
Pozdnyakov YM;
Cardiol Ther; 2018 Jun; 7(1):61-70. PubMed ID: 29779201
[TBL] [Abstract][Full Text] [Related]
15. [Trimetazidine addition to antianginal therapy: effects on efficacy and quality of life in patients with stable angina treated outpatiently].
Ter Arkh; 2012; 84(4):38-41. PubMed ID: 22774489
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the efficiency of combined pharmacotherapy with the use of trimetazidine with prolonged release in patients with stable angina in outpatient practice].
Luneva YV; Povetkin SV
Ter Arkh; 2019 Aug; 91(8):18-21. PubMed ID: 32598749
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
Ferrari R; Ford I; Fox K; Challeton JP; Correges A; Tendera M; Widimský P; Danchin N;
Lancet; 2020 Sep; 396(10254):830-838. PubMed ID: 32877651
[TBL] [Abstract][Full Text] [Related]
18. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.
McClellan KJ; Plosker GL
Drugs; 1999 Jul; 58(1):143-57. PubMed ID: 10439934
[TBL] [Abstract][Full Text] [Related]
19. Treatment of stable angina pectoris with trimetazidine modified release in Indian primary-care practice.
Gupta R; Sawhney JP; Narain VS
Am J Cardiovasc Drugs; 2005; 5(5):325-9. PubMed ID: 16156688
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effectiveness of risk minimization measures for trimetazidine: A cross sectional joint PASS survey among physicians in selected European countries.
von Bredow D; Toussi M; Samad A; Kaplan S; Domahidy M; de Voogd H; Böhmert S; Ramos RS; Arora D
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1385-1392. PubMed ID: 30379361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
